Vaxcyte, Inc. $PCVX Shares Acquired by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC raised its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 82.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,722 shares of the company’s stock after buying an additional 5,753 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Vaxcyte were worth $414,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in PCVX. AlphaQuest LLC acquired a new stake in shares of Vaxcyte during the first quarter worth $33,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Vaxcyte in the 1st quarter worth $35,000. IFP Advisors Inc raised its position in Vaxcyte by 376.4% in the first quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock valued at $62,000 after purchasing an additional 1,306 shares during the period. Blue Trust Inc. raised its position in Vaxcyte by 176.7% in the second quarter. Blue Trust Inc. now owns 2,161 shares of the company’s stock valued at $70,000 after purchasing an additional 1,380 shares during the period. Finally, Advisors Asset Management Inc. raised its position in Vaxcyte by 81.6% in the first quarter. Advisors Asset Management Inc. now owns 1,929 shares of the company’s stock valued at $73,000 after purchasing an additional 867 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on PCVX shares. Cowen restated a “buy” rating on shares of Vaxcyte in a research note on Thursday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research report on Tuesday, October 14th. Finally, The Goldman Sachs Group started coverage on Vaxcyte in a research report on Friday, September 12th. They issued a “neutral” rating and a $38.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Vaxcyte currently has a consensus rating of “Moderate Buy” and an average price target of $106.25.

Vaxcyte Stock Up 0.4%

Shares of Vaxcyte stock opened at $42.51 on Thursday. The stock has a market cap of $5.52 billion, a PE ratio of -10.34 and a beta of 1.12. The business has a fifty day simple moving average of $35.33 and a 200-day simple moving average of $33.94. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $116.00.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period last year, the business earned ($1.10) earnings per share. Analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.